Skip to main content

Table 4 Cox proportional-hazards regression model for distant-metastasis-free survival (DMFS) and breast-cancer-specific survival (BCSS) in 692 patients with tissue HER2-positive breast cancer

From: Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

Variable DMFS BCSS
  HR 95% CI P HR 95% CI P
Model with dichotomized serum HER2 ECD level, elevated vs normal
Serum HER2 ECD level, >15.2 ng/ml 3.788 2.034–7.054 <0.001a 2.564 1.230–5.343 0.012a
Tumor size, >2 cm 1.731 0.859–3.487 0.125 1.134 0.515–2.497 0.754
Lymph node positive 2.614 1.011–6.756 0.047a 2.428 0.812–7.257 0.112
Grade 3+ 1.972 1.069–3.638 0.030a 1.575 0.758–3.270 0.223
Lymphovascular invasion 2.625 1.419–4.855 0.002a 2.740 1.315–5.709 0.007a
Chemotherapy, yes 0.235 0.081–0.687 0.008a 0.303 0.085–1.078 0.065
Hormone therapy, yes 1.576 0.841–2.951 0.156 1.032 0.494–2.156 0.933
Trastuzumab, received 1.734 0.902–3.332 0.099 1.969 0.903–4.292 0.089
Model with four subgroups classified by serum HER2 ECD levels, each quartile group vs lowest-quartile subgroup
Serum HER2 ECD level,
 Lowest quartile (reference) 1    1   
 Second quartile 1.827 0.549–6.078 0.326 1.008 0.224–4.529 0.992
 Third quartile 3.029 1.003–9.152 0.049a 2.407 0.669–8.655 0.179
 Highest quartile 4.746 1.591–14.160 0.005a 2.826 0.785–10.176 0.112
Tumor size, >2 cm 1.741 0.864–3.507 0.121 1.146 0.519–2.534 0.736
Lymph node positive 2.502 0.982–6.376 0.055 2.407 0.804–7.211 0.117
Grade 3+ 1.844 1.010–3.370 0.046a 1.844 1.010–3.370 0.046a
Lymphovascular invasion 2.303 1.250–4.240 0.007a 2.550 1.223–5.317 0.012a
Chemotherapy, yes 0.210 0.074–0.599 0.004a 0.273 0.078–0.957 0.042a
Hormone therapy, yes 1.443 0.784–2.655 0.238 1.038 0.501–2.150 0.920
Trastuzumab, received 1.930 1.013–3.677 0.045a 2.098 0.968–4.549 0.061
  1. aSignificant at P < 0.05.